Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D2.395 - Erdosteine-induced multifocal fied drug eruption: a case series of five patients
D2.399 - Successful Deferasirox Desensitization in a Patient with Delayed-Type Hypersensitivity
D2.402 - Latex Sensitization as a Risk Factor for Perioperative Hypersensitivity Reactions in Asthmatic Children
D2.403 - When a Topical Drug Goes Systemic: A Case of Dual Hypersensitivity to Diltiazem
D2.405 - UnDRESSing AGEP and Revealing Erythema Multiforme
D2.406 - Severe DRESS in an oncohematological patient: diagnostic and therapeutic challenges
D2.393 - Aspirin hypersensitivity and desensitization-Sense and sensibility
D2.396 - Successful Desensitization in a Patient with a Delayed Type Hypersensitivity Reaction to Ethambutol
D2.397 - Immediate and Delayed Hypersensitivity Reactions to Multiple Thyroid Hormone Preparations: A Challenging Case
D2.400 - Vitamin Hypersensitivity in the Era of Intravenous ‘Cocktails’: Diagnostic Pitfalls and Clinical Consequences
D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region
D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor
D3.155 - Th2–Th17 immune shift following dupilumab therapy
D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry
D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download